caa a22 4500 397593295 CHVBK 20180308164945.0 cr unu---uuuuu 161202e199606 xx s 000 0 eng 10.1093/jac/37.suppl_C.1 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_C.1 Azithromycin—review of key chemical, pharmacokinetic and microbiological features [Elektronische Daten] [H. Lode, K. Borner, P. Koeppe, T. Schaberg] One of the chemical features that distinguishes the I 5-membered ring azalide azithromycin from the 14-membered ring macrolide compound erythromycin is the former's increased stability at acid pH. Azithromycin also differs pharmacokinetically from erythromycin, an important feature being azithromycin's ability to achieve high tissue concentrations, with the agent being delivered to the sites of infection by direct uptake and by targeted delivery via phagocytes. High tissue concentrations are maintained for prolonged periods because of azithromycin's long half-life, leading to once-daily dosing for 3 or 5 days. Notable microbiological features of azithromycin are in-vitro activity against many pyogenic bacteria (e.g. Neisseria gonorrhoeae and Moraxella catarrhalis), as well as organisms against which β-lactam antibiotics are usually ineffective (e.g. Legionella and Chlamydia spp.), organisms that are resistant to benzylpenicillin and erythromycin (e.g. Haemophilus influenzae) and organisms for which satisfactory therapy is limited (e.g. Toxoplasma gondii and the Mycobacterium avium-intracellulare complex). These properties of azithromycin suggest that it might be a useful agent for the treatment of a wide range of bactenal infections. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Lode H. Department of Chest and Infectious Diseases, City Hospital Zehlendorf/Heckeshorn 14109 Berlin aut Borner K. Klinikum Benjamin-Franklin, Freie Universität Berlin 12000 Berlin, Germany aut Koeppe P. Klinikum Benjamin-Franklin, Freie Universität Berlin 12000 Berlin, Germany aut Schaberg T. Department of Chest and Infectious Diseases, City Hospital Zehlendorf/Heckeshorn 14109 Berlin aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 1-8 0305-7453 37<1 1996 37 jac https://doi.org/10.1093/jac/37.suppl_C.1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_C.1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lode H. Department of Chest and Infectious Diseases, City Hospital Zehlendorf/Heckeshorn 14109 Berlin aut NATIONALLICENCE 700 1- Borner K. Klinikum Benjamin-Franklin, Freie Universität Berlin 12000 Berlin, Germany aut NATIONALLICENCE 700 1- Koeppe P. Klinikum Benjamin-Franklin, Freie Universität Berlin 12000 Berlin, Germany aut NATIONALLICENCE 700 1- Schaberg T. Department of Chest and Infectious Diseases, City Hospital Zehlendorf/Heckeshorn 14109 Berlin aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 1-8 0305-7453 37<1 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford